

**About VyGen-Bio™, Inc.:**

Visit us on the web at: [www.VyGen-Bio.com](http://www.VyGen-Bio.com)

VyGen-Bio is a discovery-stage, immunotherapy-focused biotech company developing its GEAR (Gene Edited Antibody Resistant) Cell Therapy Platform, representing a first-in-class approach to modifying immune cells to optimize therapeutic impact and patient outcomes in the treatment of hematologic malignancies. The Company is advancing towards human proof-of-concept studies to evaluate GEAR-NK natural killer cell therapy to be co-administered in combination with currently approved targeted antibodies. It is believed the GEAR-NK strategy holds the potential to advantageously eliminate the risk of NK cell fratricide while improving clinical benefit.

With operations in Florida, USA and Stockholm, Sweden, VyGen-Bio is a majority-owned subsidiary of Vycellix, Inc ([www.Vycellix.com](http://www.Vycellix.com)). The Company's platforms were discovered by research scientists based at the Cell & Gene Therapy Group at Karolinska Institute (KI), Sweden. Additionally, VyGen-Bio is a member-partner in "NextGenNK", the international Competence Center for the development of next-generation NK cell-based cancer immunotherapies based at KI and funded by Sweden's innovations agency, Vinnova. KI is globally recognized for its Nobel Assembly, which awards the Nobel Prize in Physiology or Medicine.

**Platforms:**

**GEAR-NK:** Gene-Edited Antibody Resistant NK cells (GEAR-NK) are being developed as novel cancer treatment to allow for modified NK cells to be co-administered with targeted monoclonal antibodies ("mAbs"), which in the absence of the GEAR-NK would otherwise be neutralized/eradicated by mAb therapy due to common receptor shared by both malignant cells and NK cells. GEAR-NK is expected to represent a combination cancer therapy with the potential for significantly improved outcomes for patients. The GEAR platform also holds the potential to modify hematopoietic stems cells (HSCs) in combination with mAbs to improve bone marrow transplant outcomes in the treatment of a broad range of hematological malignancies.

**GEAR DIAGNOSTICS:** Expanding on the GEAR-NK platform, a companion diagnostic is being developed as an *in vitro* screening tool to pre-determine which cancer patients are most likely to benefit from targeted mAb therapies, either as monotherapy or in combination with GEAR-NK. The GEAR-Diagnostic platform is being designed to ensure optimal patient selection, which would result in significant savings to healthcare systems and prevent patients from being subjected to ineffective therapy along with the associated side-effects which are sometimes adverse.

**VyGen-Bio Leadership:**



**Evren Alici, M.D., Ph.D., Chairman and CEO**  
Head of the Gene and Cell Therapy Group, Division of Hematology, Department of Medicine, Karolinska Institutet, Karolinska University Hospital, Stockholm



**Hans-Gustaf Ljunggren, M.D., Ph.D., Chief Medical Officer**  
Former Dean of Research, Karolinska Institutet and founder of the Center for Infectious Medicine, Department of Medicine, Karolinska Institutet, Karolinska University Hospital, Stockholm



**Arnika K. Wagner, Ph.D., Chief Scientific Officer**  
Assistant Professor, Department of Medicine, Karolinska Institutet, Karolinska University Hospital, Stockholm



**Douglas W. Calder, President**  
Board Member, Zevra Therapeutics (Nasdaq: ZVRA); Board Member, Renovaro (Nasdaq: RENB); Board Member, NextGenNK; Board Member, BioFlorida

VyGen-Bio, Inc.  
3000 North Military Trail, Suite 103  
Boca Raton, Florida 33431 USA

Douglas W. Calder, President  
Phone: 772-418-6302  
Email: [dcalder@vycellix.com](mailto:dcalder@vycellix.com)